Primary Nonresponse vs Loss of Response: Why an IBD Medication May Not Work

When an inflammatory bowel disease medication is not controlling symptoms, gastroenterologists reach for two specific terms that sound similar and mean very different things. Primary nonresponse describes a drug that never worked. Loss of response, sometimes called secondary nonresponse, describes a drug that worked and then stopped. Understanding which pattern applies to you shapes the entire next conversation: whether the dose gets raised, whether blood tests get ordered, whether a colonoscopy comes first, and which drug class your care team reaches for next.

What Primary Nonresponse Means

Primary nonresponse is the absence of meaningful improvement by the end of the induction period, the first several weeks of loading doses designed to bring inflammation down quickly. In the PANTS study, a prospective cohort of 1,610 patients with active Crohn's disease starting infliximab or adalimumab, primary nonresponse occurred in 23.8% of patients assessable at week 14. Similar figures appear with other drug classes, with roughly one in four patients with Crohn's disease or ulcerative colitis classified as primary nonresponders to ustekinumab.

Primary nonresponse has two very different underlying causes. A review of therapeutic drug monitoring during induction separates pharmacokinetic failure, where the body clears the drug too quickly for it to reach an effective concentration, from mechanistic failure, where the drug reaches good levels but the specific inflammatory pathway it targets is not the one driving your disease. Fast clearance is more likely with heavy inflammatory burden, low albumin, low hemoglobin, higher body weight, and drug loss through severely inflamed bowel.

What Loss of Response Means

Loss of response describes a return of disease activity after a period of genuine benefit. It is common and it accumulates over time. A review of infliximab in Crohn's disease calculated an annual risk of loss of response of 13% per patient-year. In ulcerative colitis, a systematic review found annual loss of response of 10.1% for infliximab and 13.4% for adalimumab, with annual dose escalation rates of 13.8% and 21.3% respectively. Roughly 72% of infliximab patients and 52% of adalimumab patients regained clinical benefit after that escalation, which is the practical reason your gastroenterologist may adjust the dose before abandoning a drug that once worked.

Immunogenicity is a leading driver. The immune system can recognize a biologic as foreign and produce anti-drug antibodies that bind it and accelerate its clearance. In PANTS, anti-drug antibodies developed in 62.8% of infliximab-treated patients and 28.5% of adalimumab-treated patients by week 54. Genetics contribute: carriage of the HLA-DQA1*05 allele substantially raises the rate of antibody formation, reaching 92% at one year among patients on infliximab monotherapy who carry it, compared with 10% among non-carriers on adalimumab combination therapy.

Why the Distinction Changes What Happens Next

The two patterns predict different odds with the next drug. A systematic review and meta-analysis of second-line biologics found that among induction trials, patients with prior primary nonresponse to an anti-TNF agent were 27% less likely to achieve remission on a second-line biologic than patients who had experienced secondary loss of response. The effect was strongest for ustekinumab and absent for vedolizumab. Someone who never responded to a first drug is more likely to need a different mechanism entirely, while someone who lost response may do well with a dose adjustment or another agent in the same class.

The Two Tests That Usually Settle It

Reactive therapeutic drug monitoring measures the amount of drug in your blood at trough, just before the next dose, along with anti-drug antibody levels. AGA guidance on therapeutic drug monitoring suggests reactive monitoring to guide treatment changes in adults with active IBD on anti-TNF therapy. An expert consensus statement on therapeutic drug monitoring reached unanimous agreement that reactive monitoring should be performed in confirmed secondary loss of response, and recommended against abandoning infliximab or adalimumab before drug concentrations of at least 10 to 15 µg/mL have been achieved.

The second test is objective confirmation that inflammation is actually present. AGA guidance on biomarkers for Crohn's disease and ulcerative colitis recommends combining biomarkers with symptoms rather than relying on symptoms alone, using a fecal calprotectin threshold of 150 µg/g and a normal C-reactive protein as evidence against active inflammation. In practice this step is often skipped. The TARGET-IBD cohort found that only 67.5% of patients had any objective disease assessment or drug level check in the 12 weeks before a dose escalation, and drug monitoring specifically was done in only 30.7%.

A Decision-Context Table

Once a drug level, an antibody titer, and an objective marker of inflammation are available, four combinations account for most treatment failures in both primary nonresponse and loss of response. The pattern holds across biologic classes, though the specific target concentrations differ by drug. The table below maps each combination to the reasoning behind the usual next step.

What the results show	What it usually means	Typical next step
Low drug level, no antibodies	Pharmacokinetic failure from fast clearance	Raise the dose or shorten the interval
Low drug level, high-titer antibodies	Immunogenic failure	Switch drugs, often with an immunomodulator added
Adequate drug level, active inflammation	Mechanistic failure	Switch to a different drug class
Adequate drug level, no inflammation	Symptoms from another cause	Investigate infection, strictures, bile acid diarrhea, or overlapping functional symptoms

These interpretations follow the consensus framework for therapeutic drug monitoring, which specifies that patients losing response because of high-titer anti-drug antibodies should be switched rather than dose-escalated.

When Symptoms Are Not Inflammation

The fourth row of that table is easy to miss and it matters. A systematic review and meta-analysis of 27 studies covering 3,169 patients found that 32.5% of people with IBD in remission still report symptoms meeting criteria for irritable bowel syndrome, 36.6% in Crohn's disease and 28.7% in ulcerative colitis. Even when remission was confirmed endoscopically, 23.5% still had these symptoms. Diarrhea, urgency, and cramping that persist alongside a normal calprotectin and a therapeutic drug level point toward a different problem, and switching biologics will not fix it.

Coming to the Appointment Prepared

The evidence that separates primary nonresponse from loss of response is largely historical: when you started the drug, whether symptoms improved and by how much, when they came back, and what happened around that time. Missed or delayed doses, a course of steroids, an infection, or a stretch of dose spacing all change the interpretation of a low drug level. Writing down the sequence before your visit, with approximate dates for infusions or injections, symptom changes, and any lab results you have, gives your gastroenterologist the raw material to classify the pattern and order the right test rather than reconstructing the timeline from memory in a fifteen-minute appointment.